Regeneron, Lilly Reveal Positive Results for Antibody Combos (2)

Regeneron Pharmaceuticals Inc. and Eli Lilly and Co. each reported positive results from Covid-19 antibody drug combinations Tuesday, as both companies seek to expand use of their therapies and ensure effectiveness against new strains.

Regeneron said its antibody cocktail reduced Covid-19 cases by half and prevented all symptoms in people at high risk of catching the coronavirus. A combination of two antibodies that Lilly’s advancing to combat new variants cut the chances of hospitalizations and deaths by 70% in high-risk patients.

The two data sets “underscore the importance of antibody treatments,” Cantor Fitzgerald analyst Louise Chen wrote in a Tuesday ...